Indirect costs associated with metastatic breast cancer

Journal of Medical Economics

Volumn 16, Issue 10, 2013, Pages 1169-1178

  Wan, Yin ^a   Gao, Xin ^a   Mehta, Sonam ^a   Wang, Zhixiao ^b   Faria, Claudio ^b   Schwartzberg, Lee ^c  

^a PHARMERIT INTERNATIONAL   (United States)

^b EISAI INC   (United States)

^c WEST CLINIC   (United States)

Author keywords

Employer; Indirect costs; Metastatic breast cancer; Productivity loss

Indexed keywords

ADULT; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; POPULATION; PRODUCTIVITY; PROPENSITY SCORE; SALARY AND FRINGE BENEFIT;

ADOLESCENT; ADULT; BREAST NEOPLASMS; COST OF ILLNESS; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; EFFICIENCY; FEMALE; HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, DISABILITY; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SICK LEAVE; UNITED STATES; YOUNG ADULT;

EID: 84884557008     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.826228     Document Type: Article

References (28)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society, 2011
2. World Health Organization. Cancer. Fact sheet no. 297. Geneva: World Health Organization, 2011
3. Jatoi I, Chen BE, Anderson WF, et al. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007;25:1683-90 (Pubitemid 46797948)
4. Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer 2010;10:64-73
5. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA: Cancer J Clinicians 2008;49:8-31
6. Roche H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 2011;22:1000-10
7. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol 2006;33(1 Suppl 2): S2-5 (Pubitemid 43201977)
8. National Cancer Institute. A snapshot of breast cancer. 2009. http://www. cancer.gov/aboutnci/servingpeople/snapshots/breast.pdf. Accessed 2011
9. Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 2009;27:199-209
10. Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health 2000;3:23-30 (Pubitemid 30232945)
11. Shih YCT, Elting LS, Pavluck AL, et al. Immunotherapy in the initial treatment of newly diagnosed cancer patients: utilization trend and cost projections for non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Metastatic Colorectal Cancer. Cancer Invest 2010;28:46-53
12. Fu AZ, Chen L, Sullivan SD, et al. Absenteeism and short-term disability associated with breast cancer. Breast Cancer Res Treat 2011;130:235-42
13. Lidgren M, Wilking N, Jonsson B, et al. Resource use and costs associated with different states of breast cancer. Int Technol Assess Health Care 2007;23:223-31 (Pubitemid 46642729)
14. Singer PA, Bowman KW. Quality care at the end of life. BMJ 2002;324: 1291-2 (Pubitemid 34606767)
15. Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. Can Med Assoc J. 2004;170:1795-801 (Pubitemid 38833404)
16. United States Department of Labor United. Wage and Hour Division (WHD) - Family and Medical Leave Act. 2010. http://www.dol.gov/whd/fmla/. Accessed September, 2012
17. States Bureau of Labor Statistics. Usual Weekly Earnings of Wage and Salary Workers. 2012. http://www.bls.gov/news.release/wkyeng.toc.htm. Accessed October 2012
18. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. 2001. In SAS SUGI 26, Paper 214-26
19. Motulsky H. Intuitive biostatistics: a nonmathematical guide to statistical thinking. USA: Oxford University Press, 2010
20. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004;9:197-204 (Pubitemid 39424759)
21. Myers RH, Montgomery DC. A tutorial on generalized linear models. J Qual Technol 1997;29:274-91 (Pubitemid 127617647)
22. Drolet M, Maunsell E, Mondor M, et al. Work absence after breast cancer diagnosis: a population-based study. CMAJ 2005;173:765-71
23. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-8 (Pubitemid 26337709)
24. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. USA: Oxford University Press, 2005
25. Bradley CJ, Neumark D, Bednarek HL, et al. Short-term effects of breast cancer on labor market attachment: results from a longitudinal study. J Health Econ 2005;24:137-60 (Pubitemid 40023076)
26. Foster TS, Miller JD, Boye ME, et al. The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev 2011;37:405-15
27. Schmid-Bu? chi S, Halfens RJG, Dassen T, et al. A review of psychosocial needs of breast-cancer patients and their relatives. J Clin Nurs 2008; 17:2895-909
28. Adamson DM, Chang S, Hansen LG. Health research data for the real world: The MarketScan databases. New York: Thompson Healthcare, 2008